Sandoz Fights FDA Exclusivity For Sanofi MS Drug At DC Circ.
Novartis unit Sandoz is continuing its fight against the U.S. Food and Drug Administration's decision to give exclusivity to a Sanofi multiple sclerosis drug, saying at the D.C. Circuit that the...To view the full article, register now.
Already a subscriber? Click here to view full article